. 2016 Aug 9;8(33):54115–54135. doi: 10.18632/oncotarget.11132

Table 2. Comparison of tumorigenic cell doses between BEAS2B^Ve^h and BEAS2B^CD164 cell.

Cell type	Cell number	Number of tumors/number of injections	Tumor onset time (weeks)
BEAS2B^Veh	10000	0/2 (0%)	-
	500	3/5 (60%)	3-4
BEAS2B^CD164	1000	3/3 (100%)	2-3
	10000	6/6 (100%)	2

Table 2. Comparison of tumorigenic cell doses between BEAS2BVeh and BEAS2BCD164 cell.